



April 6, 2016

## **Mylan Launches Generic Epivir® Tablets**

HERTFORDSHIRE, England and PITTSBURGH, April 6, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Lamivudine Tablets USP, 150 mg and 300 mg, which is the generic version of ViiV Healthcare's Epivir® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Lamivudine Tablets is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.(1)

Lamivudine Tablets USP, 150 mg and 300 mg, had U.S. sales of approximately \$27.1 million for the 12 months ending Dec. 31, 2015, according to IMS Health.

Currently, Mylan has 265 ANDAs pending FDA approval representing \$110.3 billion in annual brand sales, according to IMS Health. Forty-eight of these pending ANDAs are potential first-to-file opportunities, representing \$38.3 billion in annual brand sales, for the 12 months ending Dec. 31, 2015, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at [mylan.com](http://mylan.com).

(1) Use of Lamivudine has been associated with lactic acidosis and fatty liver disease. In patients who are co-infected with hepatitis B virus and HIV-1, severe acute exacerbations of Hepatitis B have occurred upon discontinuation of lamivudine.

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/mylan-launches-generic-epivir-tablets-300247142.html>

SOURCE Mylan N.V.

News Provided by Acquire Media